NCT01240577已完成1 期
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- -Measure plasma concentrations of IPdR, IdUrd, and IdUrd metabolites after a single oral dose of IPdR.-Determine the safety of administering a single oral dose of IPdR.
研究概览
简要总结
Background:
- The experimental drug IPdR is broken down in the body to IdUrd, which has been given to patients to find out if it can improve radiation therapy. IdUrd has to be given through a vein; therefore this new drug (IPdR) has been made which can be taken by mouth. Researchers are interested in determining whether IPdR should also be studied to find out if it can improve radiation therapy. The current study is to find out if people absorb the drug given by mouth.
Objectives:
- To evaluate the levels of drug and its breakdown products in the blood following a single dose of IPdR by mouth. .
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with cancer (solid tumors or lymphomas) that have not responded to standard treatment.
Design:
- This study involves an initial dosing visit, one day of admission to the hospital for blood work, and a follow-up visit 14 days later.
- Participants will be screened with a physical examination and medical history, as well as blood and urine samples.
- Participants will receive a single dose of IPdR, and will provide multiple blood and urine samples for 24 hours after administration of the drug.
- Fourteen days after receiving IPdR, participants will have another physical examination and additional blood and urine tests to evaluate how IPdR has been broken down by the body.
- Cancer treatment will not be provided as part of this protocol.
详细描述
Background:
- The nucleoside analog iododeoxyuridine (IdUrd, NSC 39661) has shown promising activity as a radiosensitizer in preclinical models and has been evaluated in Phase I/II clinical trials. The extent of radiosensitization is directly related to the incorporation of IdUrd into tumor DNA as a replacement for thymidine.
- IPdR (NSC 726188) is an orally administered prodrug of IdUrd with a better therapeutic index in preclinical models.
- This first in human study of IPdR will evaluate whether IPdR is absorbed and what plasma levels of IPdR and its major metabolite, IdUrd, are achieved after a single oral dose.
Objectives:
- Measure plasma concentrations of IPdR, IdUrd, and IdUrd metabolites after a single oral dose of IPdR
- Determine the safety of administering a single oral dose of IPdR.
Eligibility:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 110 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA:
- •Patients must have histologically documented (confirmed at the Laboratory of Pathology, NCI) solid tumors or lymphoid malignancies that are refractory to at least one line of standard treatment or for which no standard therapy is available. Patients with lymphoid malignancies may be enrolled if they have disease for which standard therapy is currently not indicated. Patients should not have disease-associated symptoms requiring immediate therapy or intervention.
- •Any prior chemotherapy or radiation therapy must have been completed greater than or equal to 2 weeks prior to enrollment (6 weeks for nitrosoureas or mitomycin C), and the patient must have recovered to eligibility levels from prior toxicity.
- •Age greater than or equal to 18 years. Patients under 18 years of age are excluded because of their inability as a protected population to give appropriate consent to this non-therapeutic study.
- •ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).
- •Life expectancy of at least 3 months.
- •Patients must have normal organ and marrow function as defined below:
- •absolute neutrophil count greater than or equal to 1,500/microL
- •platelets greater than or equal to 100,000/microL
- •total bilirubin less than 1.5 times institutional upper limit of normal (ULN)
- •AST(SGOT)/ALT(SGPT) less than or equal to 3.0 times ULN
- •creatinine less than 1.5 times ULN
- •-creatinine clearance greater than or equal to 60 mL/min for patients with creatinine levels greater than or equal to 1.5 times ULN
- •IPdR is a nucleoside analog and therefore potentially teratogenic. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study drug administration. Because there is an unknown but potential risk for adverse events in nursing infants secondary to IPdR administration to the mother, nursing mothers should not receive IPdR.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Patients may not be receiving any other investigational agents.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, GI conditions limiting absorption, serious skin conditions, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Women who are pregnant or nursing.
- •INCLUSION OF WOMEN AND MINORITIES:
- •Both men and women and members of all races and ethnic groups are eligible for this trial.
结局指标
主要结局
-Measure plasma concentrations of IPdR, IdUrd, and IdUrd metabolites after a single oral dose of IPdR.-Determine the safety of administering a single oral dose of IPdR.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184HealthyNCT01824446Shire6
已完成
1 期
A Study of LY2605541 and Insulin Lispro Mixture in Healthy ParticipantsHealthy VolunteersNCT01871493Eli Lilly and Company40
已完成
1 期
Single Oral Dose Escalation Study of DNDI-0690 in Healthy SubjectsVisceral LeishmaniasisCutaneous LeishmaniasesNCT03929016Drugs for Neglected Diseases64
已完成
1 期
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in VolunteersHealthyNCT02994732BioMed Valley Discoveries, Inc6
Unknown
1 期
A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy VolunteersHIV-1-infectionTuberculosisNCT03199690St. Stephens Clinical Research16